Literature DB >> 12077614

Can ivermectin mass treatments eliminate onchocerciasis in Africa?

M Winnen1, A P Plaisier, E S Alley, N J D Nagelkerke, G van Oortmarssen, B A Boatin, J D F Habbema.   

Abstract

OBJECTIVE: To elucidate the conditions in which mass treatment with ivermectin reduces the transmission of Onchocerca volvulus sufficiently to eliminate infection from an African community.
METHODS: ONCHOSIM, a microsimulation model for onchocerciasis transmission, was used to explore the implications of different treatment intervals, coverage levels and precontrol endemicities for the likelihood of elimination.
FINDINGS: Simulations suggested that control strategies based exclusively on ivermectin mass treatments could eliminate onchocerciasis. The duration of treatment required to eliminate infection depended heavily on the treatment programme and precontrol endemicity. In areas with medium to high levels of infection, annual mass treatments with 65% coverage for at least 25 years were necessary. Model predictions suggested that durations exceeding 35 years would be required if there were much heterogeneity in exposure to vector bites and, consequently, wide individual variation in microfilaria counts. If the treatment interval were reduced from 12 to 6 months the time for completion of the programme could be more than halved and elimination could be accomplished in areas of hyperendemicity, provided that the effects of each treatment would be the same as with annual treatments. However, it was doubtful whether high coverage levels could be sustained long enough to achieve worldwide eradication.
CONCLUSION: Elimination of onchocerciasis from most endemic foci in Africa appears to be possible. However, the requirements in terms of duration, coverage, and frequency of treatment may be prohibitive in highly endemic areas.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12077614      PMCID: PMC2567795     

Source DB:  PubMed          Journal:  Bull World Health Organ        ISSN: 0042-9686            Impact factor:   9.408


  70 in total

1.  Seventeen years of annual distribution of ivermectin has not interrupted onchocerciasis transmission in North Region, Cameroon.

Authors:  Moses N Katabarwa; Albert Eyamba; Philippe Nwane; Peter Enyong; Souleymanou Yaya; Jean Baldiagaï; Théodore Kambaba Madi; Abdoulaye Yougouda; Gervais Ondobo Andze; Frank O Richards
Journal:  Am J Trop Med Hyg       Date:  2011-12       Impact factor: 2.345

2.  Transmission of Onchocerca volvulus by Simulium neavei in Mount Elgon focus of Eastern Uganda has been interrupted.

Authors:  Moses Katabarwa; Tom Lakwo; Peace Habomugisha; Stella Agunyo; Edson Byamukama; David Oguttu; Richard Ndyomugyenyi; Ephraim Tukesiga; Galex Orukan Ochieng; Francis Abwaimo; Ambrose Onapa; Dennis W K Lwamafa; Frank Walsh; Thomas R Unnasch; Frank O Richards
Journal:  Am J Trop Med Hyg       Date:  2014-03-31       Impact factor: 2.345

3.  Impact of long-term treatment of onchocerciasis with ivermectin in Kaduna State, Nigeria: first evidence of the potential for elimination in the operational area of the African Programme for Onchocerciasis Control.

Authors:  Afework Hailemariam Tekle; Elizabeth Elhassan; Sunday Isiyaku; Uche V Amazigo; Simon Bush; Mounkaila Noma; Simon Cousens; Adenike Abiose; Jan H Remme
Journal:  Parasit Vectors       Date:  2012-02-07       Impact factor: 3.876

Review 4.  The pharmacokinetics and interactions of ivermectin in humans--a mini-review.

Authors:  Aránzazu González Canga; Ana M Sahagún Prieto; M José Diez Liébana; Nélida Fernández Martínez; Matilde Sierra Vega; Juan J García Vieitez
Journal:  AAPS J       Date:  2008-01-25       Impact factor: 4.009

5.  Vaccines to combat river blindness: expression, selection and formulation of vaccines against infection with Onchocerca volvulus in a mouse model.

Authors:  Jessica A Hess; Bin Zhan; Sandra Bonne-Année; Jessica M Deckman; Maria Elena Bottazzi; Peter J Hotez; Thomas R Klei; Sara Lustigman; David Abraham
Journal:  Int J Parasitol       Date:  2014-06-05       Impact factor: 3.981

6.  Household-wide ivermectin treatment for head lice in an impoverished community: randomized observer-blinded controlled trial.

Authors:  Daniel Pilger; Jorg Heukelbach; Adak Khakban; Fabiola Araujo Oliveira; Gernot Fengler; Hermann Feldmeier
Journal:  Bull World Health Organ       Date:  2009-12-21       Impact factor: 9.408

7.  Compliance with eight years of annual ivermectin treatment of onchocerciasis in Cameroon and Nigeria.

Authors:  William R Brieger; Joseph C Okeibunor; Adenike O Abiose; Samuel Wanji; Elizabeth Elhassan; Richard Ndyomugyenyi; Uche V Amazigo
Journal:  Parasit Vectors       Date:  2011-07-27       Impact factor: 3.876

8.  Onchocerca volvulus-specific antibody and cytokine responses in onchocerciasis patients after 16 years of repeated ivermectin therapy.

Authors:  C S Mai; D M Hamm; M Banla; A Agossou; H Schulz-Key; C Heuschkel; P T Soboslay
Journal:  Clin Exp Immunol       Date:  2007-03       Impact factor: 4.330

Review 9.  The natural progression of Gambiense sleeping sickness: what is the evidence?

Authors:  Francesco Checchi; João A N Filipe; Michael P Barrett; Daniel Chandramohan
Journal:  PLoS Negl Trop Dis       Date:  2008-12-23

10.  Feasibility of onchocerciasis elimination with ivermectin treatment in endemic foci in Africa: first evidence from studies in Mali and Senegal.

Authors:  Lamine Diawara; Mamadou O Traoré; Alioune Badji; Yiriba Bissan; Konimba Doumbia; Soula F Goita; Lassana Konaté; Kalifa Mounkoro; Moussa D Sarr; Amadou F Seck; Laurent Toé; Seyni Tourée; Jan H F Remme
Journal:  PLoS Negl Trop Dis       Date:  2009-07-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.